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In-vivo studies on kappa 
opioid receptors 
Alan Cowan and Debra E. Gmerek* 
The actions of opioids are mediated by multiple types of opioid receptor. As a 
result, 'obtaining the right balance' is the catchphrase most frequently heard 
these days in analgesic research laboratories throughout the pharmaceutical 
industry. Tomorrow's analgesics will feature a prominent K component, a touch 
of 6, a tickle of ~, but not even a wisp of o. New compounds are fashioned largely 
from structure-activity relationships involving bioassays and radioligand 
receptor binding. These in-vitro approaches have become well established over 
the past decade since they help to link receptor type to the analgesic under 
investigation. What about the complementary preclinical tests in-vivo? 
Specifically, how can the animal pharmacologist assist in characterizing K 
opioid activity? In this article, Alan Cowan and Debra E. Gmerek present a 
survey of tests that are being used to detect and define K activity in-vivo. 
Special emphasis is placed on the rat bombesin-scratch test, a new procedure in 
which several K-preferring agents are selectively active. 
Compounds  that are classified as K- 
agonists (e.g. tifluadom, U-50488; 
U-50088 is trans3,4-dichloro-N- 
methyl-N- [2-(1-pyrrolidinyl)-cyclo- 
hexyl 1]-benzeneacetamide); usually 
on the basis of bioassay and 
binding activity profile, are gener- 
ally perceived to be safer than the 
traditional morphine-like or ~-agon- 
ists. This view derives from the 
differentpharmacologies of ~- and K- 
agonists, a topic that has been 
analysed at length 1. In short, K- 
agonists are of interest because they 
offer diversity in chemical structure, 
antinociception, a milder form of 
physical dependence, and limited 
actions on respiration and gastro- 
intestinal transit. Unfortunately, 
with many of the older K-agonists, 
the price paid for the pleasing 
profile was the emergence of un- 
wanted dysphoric and psychoto- 
mimetic (i.e. o) side-effects. Nalor- 
phine, the historic narcotic antag- 
onist analgesic, was clinically aban- 
doned for this reason. Dysphoria 
and altered perception have been 
associated with some of the more 
recently described I<-agonists (e.g. 
the benzomorphans, ketazocine 
and MR 2034, i.e. (--)-(1R,5R,9R,2"S), 
5,9-dimethyl-2-tetrahydrofurfuryl- 
2'-hydroxy-6,7-benzomorphan). 
The finding that ketazocine can 
cause unpleasant symptoms in 
humans 2 is conceptually import- 
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ant, given that this compound was 
introduced as the prototype agon- 
ist at K receptors 1. Cross-reaction 
between K and o opioid receptors 
is clearly a major worry in the 
commercial development of K- 
agonists as potential analgesics. 
Another concern is the possibility 
that i< receptors per se (also) 
mediate some of the disagreeable 
subjective effects associated with 
acute administration of certain K- 
agonists to humans. 
A key objective of analgesic drug 
development throughout K- 
research has been to manoeuvre 
between and beyond the twin 
threats of physical dependence 
and negative central effects. Many 
groups accepted the challenge, 
believing that the ideal K analgesic, 
although elusive, can ultimately be 
designed. At the moment,  a clini- 
cal opinion on full, selective K- 
agonists of the tifluadom and U- 
50488 type has still to be formed. 
Pharmacological profiles of 
K-agonists in rodents 
A screening cascade for K act- 
ivity conventionally starts with 
bioassays and radioligand recep- 
tor binding. Next, the subtle twists 
of antinociceptive testing are tackl- 
ed. The selection of particular tests 
is dependent on the philosophy 
behind the analgesic project e.g. 
the relative balance of receptor 
activities that is perceived to be 
ideal for the target pain state in 
man. Selection of antinociceptive 
method and route of admini- 
stration is also dependent on 
whether the primary focus of 
action is deemed to be spinal, 
supraspinal, or in the periphery. A 
pharmaceutical company search- 
ing for its own tifluadom or U- 
50488 might well choose mouse 
abdominal constriction and hot 
plate tests to establish levels of 
antinociception and reversibility 
by naloxone 3. Differences between 
test compounds may be empha- 
sized by using supraspinal (i.c.v.) 
and spinal (intrathecal) routes of 
administration 4-6. For example, U- 
50088, ketazocine and morphine 
are all active after intrathecal 
administration in the mouse (0.6% 
acetic acid) writhing test but  only 
morphine is active by the i.c.v. 
route. It seems that K-receptors 
modulate visceral pain at spinal, 
but not at supraspinal, levels in 
this procedure (Porreca, Mosberg, 
Burks and Cowan, unpublished 
data). Note, however, that the 
choice of noxious stimulus is 
critical. Indeed, the quality of the 
stimulus used has long been 
considered a key variable in the 
evaluation of novel analgesics. 
This point is obvious when results 
from the mouse hot plate (55°C) 
test are compared. In this test, U- 
50088 has unimpressive efficacy 
and potency when given by i.c.v. 
or intrathecal administration 
whereas morphine is still active by 
either route s . 
The next level of testing includes 
procedures that help to further 
distinguish tifluadom and U-50488 
from ~-agonists such as morphine. 
Several approaches are outlined in 
Table I. There is no common 
consensus on the best mix of 
methods. The flurothyl test 7 con- 
trasts markedly with the bomb- 
esin-scratch test in that ethyl- 
ketazocine, tifluadom and U-50088 
are active in the latter and inactive 
in the former. Morphine is not 
active against bombesin but raises 
the seizure threshold (along with 
several other ~-agonists) in rats 
exposed to flurothyl, a volatile 
convulsant. 
The rat bombesin-scratch test 
The bombesin-scratch test (Ref. 
8; see Fig. 1) is a recent addition to 
those in-vivo methods that can be 
used in the evaluation of com- 
pounds with activity at i< recep- 
tors. Bombesin, a tetradecapeptide 
originally isolated from frog skin 
in 1971, is one of a surprisingly 
large number  of well-known en- 
dogenous substances which cause 
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Fig. 1. Scratching caused by bombesin O. 10 p,g, Lc.v. 
excessive scratching and/or 
grooming when given centrally to 
rodents (e.g. prolactin, SP and 
vasopressin). Reasons for these 
behaviours have yet to be es- 
tablished. Neuropeptide-induced 
grooming/scratching in rats can 
be altered in different ways 
by subcutaneously administered 
morphine and naloxone 9-11. Thus, 
the excessive grooming and/or 
scratching associated with ACTHl_24 
is attenuated by both mor- 
phine and naloxone; that asso- 
ciated with thyrotropin releasing 
hormone (TRH) is suppressed by 
morphine but not by naloxone; 
while that associated with bomb- 
esin is unaffected by both mor- 
phine and naloxone. The resist- 
ance of bombesin towards mor- 
phine prompted testing of many 
opioids and opioid peptides in an 
attempt to suppress the robust 
scratching elicited by bombesin,' 
in rats. The initial results revealed 
that several mixed agonist--antago- 
nists/K-agonists attenuated bomb- 
esin-induced scratching in a ste- 
reoselective and dose-related man- 
ner. Examples of these agents (all 
benzomorphans) are bremazocine, 
cyclazocine, ethylketazocine, ket- 
azocine and (-)pentazocine; they 
seem to share pharmacological 
effects in rats that dispel 
the animals' preoccupation with 
scratching. Other commonly used 
opioids (mainly tt-agonists) and 
opioid peptides were ineffective 
against bombesin when tested 
at behaviourally nondepressant 
doses. Examples of inactive com- 
pounds were buprenorphine, 
levorphanol, meperidine, metha- 
done, metkephamid and ~-endor- 
phin. The scratching was essen- 
tially unaffected by behaviouraUy 
nondepressant doses of haloperi- 
dol, indometacin, lidocaine, 
neurotensin and several antihista- 
minic/antiserotoninergic agents. 
Suppression of bombesin-indu- 
ced scratching by ethylketazocine 
seems to involve stereospecific 
o p i o i d  binding sites since ( - )  nal- 
oxone, but not (+)naloxone, 
attenuated the antibombesin effect 
of ethylketazocine s. The following 
observations implicate Jc, rather 
than ~, binding sites: (1) multiple 
injections of morphine did not 
influence the ability of ethyl- 
ketazocine to antagonize bomb- 
esin, and (2) when ~-receptors were 
blocked with buprenorphine, 
ethylketazocine still antagonized 
bombesin-induced scratching. 
One puzzling result was the 
inclusion of phenazocine (gener- 
ally regarded as a ~t agonist in vivo) 
in the list of active agents (Table II). 
Since all compounds showing 
antibombesin effects were benzo- 
morphans (including phenazo- 
cine), the question of K- v. benzo- 
morphan-selective binding sites 
needed to be addressed. Recent 
experiments with nonbenzomor- 
phan K-agonists (tifluadom and U- 
50488H) showed that these agents 
are active in the procedure (Table 
II) and can be antagonized in a 
dose-related manner by naloxone. 
It may be concluded that the 
bombesin-scratch test is a useful 
addition to the list of ic evaluative 
methods outlined in Table I. 
As a postscript to the test, note 
that there is a link between this 
less common measure - scratching 
- and K compounds, that stretches 
back to the early 1970s. At that 
time, it was noticed that monkeys, 
receiving it-directed mixed agonist- 
antagonists such as cyclazocine 
and nalorphine for a month, 
scratched excessively when they 
were withdrawn from these agents 
or were challenged with nalox- 
one z2. Scratching was also obser- 
ved during withdrawal from cer- 
tain bridged oripavines, com- 
pounds that were classified as K- 
preferring almost a decade later 13. 
Recent work from the University of 
Michigan has shown that rhesus 
monkeys undergoing abrupt with- 
drawal from U-50488 (but not from 
morphine) also display an unusu- 
ally high incidence of scratching 1~. 
Interestingly, this behaviour is 
suppressed by fifluadom but not 
by morphine. 
O t h e r  t e s t s  
Other tests show that morphine- 
like agonists have antidiuretic 
effects. K-Agonists are completely 
T A B L E  I. Pharmacological profiles of test agents after peripheral administration 
Procedure Ethylketazocine Tifluaclom U-50488 Morphine 
Rata 
Bombesin-scratch test + + + - 
Increased flurothyl thresholds - - - + 
Diuresis + + + - 
Increased food intake + + + --- 
Inhibition of gastrointestinal 
transit + - - + 
R h e e t a l  m o n k e y s  
Nalorphine discrimination + + + - 
Morphine-withdrawal 
suppression - - - + 
+ = positive or dose-related effect. _+ = equivocal.  - = no consistent effect. 
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TABLE II. Effects of representative opioids and opioid peptides On bombesin-induced 
scratching in rats" 
Test agent Aso (mg kg -~ s.c.) 
Ethylketazocine 0.36 (0.3,3--0.40) b 
U-50488 6.61 (5.37-8.13) 
Tifluadom 6.80 (5.52-8.36) 
Phenazocine 0.29 (0.19-0.43) 
Morphine >10 ¢ 
Meperidine >25 
Metkephamid >30 
I~-endorphin > 10 I~] i.c.v. 
• The standard dose of bombesin was 0.10 p,g i.c.v, t'95% Confidence limits. ¢Highest 
behaviourally nondepressant dose tested. 
different. Water  diuresis  seems to 
be an inherent  proper ty  of virtu- 
ally all known *:-agonists, at least in 
rats and monkeys  (ketazocine and 
MR 2033 are diuret ic in man; MR 
2033 is (+)-(1R,5R,9R,2"S)-5,9-di- 
methyl-2-tetrahydrofurfuryl-2'-hy- 
droxy-6,7benzomorphan).  One 
current theory is that *:-agonists 
suppress  vasopressin release from 
the neurohypophys i s  and this 
leads to increased ur ine output.  
There may be a per ipheral  site of 
action in the rat since bilateral 
adrenal  demeduUation abolishes 
K-mediated diuresis  ~s. At a practi-  
cal level, diuresis  is undoubted ly  
the most popular approach in v ivo  
for comparing new and s tandard *: 
directed ligands. Reasons for this 
are quite clear. Increased urine 
output  represents  a simple, dis t in-  
guishing feature of K-agonists. 
Examination of dose- response  
curves, along with  interactional 
s tudies wi th  morphine ,  bremazo-  
cine and ~-funaltrexamine (i.e. the 
~-fumaramate methyl  ester of nal- 
trexone) (an irreversible ~t- 
antagonist  in v i tro) ,  allows differ- 
ent iat ion wi th in  the K class e.g. 
ethylketazocine from U-50488 and 
from nalorphine  16. Parenthetically, 
, : -preferring opio id  pept ides  also 
seem to be active in the diuresis  
test since dynorphin-A,  the endo-  
genous K ligand, increases urina-  
t ion wi th in  1-2 h of i.c.v, adminis-  
tration to normally hydra ted  rats 17. 
[D-Pen 2, D-PenS]enkephalin, prob-  
ably the most  selective agonist  at 
5-opioid  receptors that is currently 
available is, has no marked in- 
fluence on urine output  17. 
Dynorph in-A (i.c.v.) init iates 
feeding in rats. This action is antago- 
nized by  naloxone. Ethylketazo- 
cine, t i f luadom and U-50488 like- 
wise induce feeding (after s,c. 
Injection) but  morphine  is often 
ineffective in drug-naive  rats 19. 
Morphine  can be more dear ly  
d is t inguished from tif luadom and 
U-50488 in the rat charcoal meal 
test. In this procedure,  morphine  
delays the passage of charcoal 
along the GI tract in a dose-related 
manner  but  t if luadom and U-50488 
are wi thout  major effects 2°. Ethyl- 
ketazocine resembles morphine  
rather than t if luadom and U-50488 
in this test; the anti transit  action of 
ethylketazocine is probably  medi-  
ated by  ~t-receptors. 
Studies with K-agonists in 
monkeys  
Knowledge that several opioids  
can function as discriminat ive 
st imuli  to control the behaviour  of 
animals is ut i l ized in more ad- 
vanced levels of testing. For the 
evaluation of *: activity, drug 
discr iminat ion experiments  use 
animals that are trained to respond 
in ei ther one way or another 
depending  on the presence or 
absence of the interoceptive cues 
associated with  injection of *:- 
agonists. The work of Tang and 
Code 21 provides a good example. 
They found that rhesus monkeys,  
t rained to discriminate the phar-  
macological effects of nalorphine 
(a K-agonist in this species) from 
saline, generalized completely to 
ethylketazocine, t if luadom and U- 
50488 but  (critically) not to three ~- 
agonists - morphine,  methadone 
and meperidine.  
Monkeys have also been used in 
morphine-wi thdrawal  suppres-  
sion studies (at the Universi ty of 
Michigan) to characterize K-direc- 
ted ligands. Behaviourally nonde-  
pressant  doses of ethylketazocine, 
t if luadom and U-50488 (in contrast 
to morphine)  do not  suppress  
signs of wi thdrawal  in 14h 
wi thdrawn,  morph ine -dependen t  
monkeys  14. In these animals,  a 
wel l -known behavioural  syn- 
drome emerges (e.g. excessive 
vocalization, abdominal  defense 
reactions, vomiting) 22. The syn- 
drome associated with  depriva-  
t ion- induced wi thdrawal  from U- 
50488 is quali tat ively different; as 
already indicated,  scratching is 
prominent ,  along with picking at 
71 
fingers and toes, and frequent 
grooming of other monkeys  14. 
Future trends 
Discovering new and bet ter  
analgesics is no easy matter. We 
may have to settle for less than 
ideal opioids,  and only modes t  
gains, at least in the short term. 
Perhaps the growing emphasis  on 
'nonopio id '  pa in  modulat ing sys- 
tems, both  central and peripheral ,  
will foster a rate of drug intro- 
duction more in keeping with 
academic advances. In the mean-  
time, opioids  wi th  various activi- 
ties at ~, K and 6 receptors are 
undergoing clinical trials. The evalua- 
tion of key compounds from chemical 
classes as disparate as benzene- 
acetamide (U-62066; 5(x,7a,8~-(+)-3, 
4-dichlom-N)-methyl-N(7-(1-pyrro- 
l idinyl)-  1-oxaspiro-(4,5)dec-8-yl) 
benzene + acetamide) and mor- 
phinan  (xorphanol) should pro- 
vide  the miss ing and vital links 
between clinical analgesia, subjec- 
tive effects, antinociception and 
balance of receptor activities. For 
better  or for worse, results from 
studies such as these will have a 
profound influence on the way~ 
analgesic researchers pursue  elu- 
sive anodyne.  
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Short and concise 
handling of drug 
interactions 
Drug interactions, 5th edn 
by Phi l ip  D. Hans t en ,  Lea & Febiger, 
1985. $24.75 (x + 460 pages) I S B N  
0 8121 0944 9 
There are so many drugs available 
that it is quite impossible for 
anyone to be able to remember 
with any certainty more than a 
handful of drugs which can, and 
which cannot, be safely admini-  
stered together. The philosophy 
behind the writ ing of the first 
edition of this book, published in 
1971, and behind the writing of all 
of the subsequent  editions, has 
been to offer a solution to the 
problem of drug interactions by 
providing concise information in a 
helpful and down-to-earth style 
which can be used when drugs are 
being prescribed or dispensed. So 
it is essentially a practical reference 
book. If you want a discursive and 
detailed treatise on the pharmaco- 
logical mechanisms which underly 
the interactions between drugs, 
then this book is not for you 
(although you might find it very 
helpful in point ing your nose in 
the right direction). But if, on the 
other hand, you are looking for a 
practical manual  which offers 
direct guidance, then this book 
will fit the bill very nicely. 
The author has divided the book 
into a number  of chapters which 
neatly categorize drugs into thera- 
peutic or chemical groupings 
( 'Anticoagulants',  'Anticonvul-  
sants', 'Phenothiazines' ,  etc.) and 
then subdivided the drugs which 
fall into these categories alpha- 
betically. A further subdivision 
allows the interactions of particu- 
lar drug-drug pairs to be dealt 
with in summary form under  the 
headings of 'Mechanism',  'Clinical 
Significance' and 'Management ' .  
The summaries are for the most 
part short and concise, and are 
referenced with superscript num-  
bers which refer to bibliographies 
at the end of each chapter. Gener- 
ally speaking, the size of the 
summary is some indication of the 
extent of the knowledge of the 
interaction in question. And, of 
course, as is to be expected of a 
reference book, there is a good 
index at the back of the book which 
uses for the most part generic 
names, but  with a sprinkling of 
proprietary names as well. Those 
familiar with previous editions 
will note that the section which 
was given over to effects on clinical 
laboratory results is missing. This, 
we are told in the introduction, is 
to be published separately later. 
Professor Hansten is one of the 
